High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: A phase II trial of the sarah cannon oncology research consortium

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages

  Hainsworth, John D ^a,b   Shipley, Dianna L ^a,b   Reeves Jr , James ^a,c   Arrowsmith, Edward R ^a,d   Barnes, Edward K ^a,b   Waterhouse, David M ^a,e  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^d Chattanooga Oncology Hematology Associates   (United States)

^e Oncology Hematology Care   (United States)

Author keywords

Bevacizumab; Clear cell; Phase II; Renal carcinoma

Indexed keywords

BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLEAR CELL CARCINOMA; COLITIS; CONFUSION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FEMALE; GASTROENTERITIS; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; THROMBOSIS; TRACHEOESOPHAGEAL FISTULA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

BEVACIZUMAB; CLEAR CELL; PHASE II; RENAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883458683     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.014     Document Type: Article

References (15)

1. R.J. Motzer, T.E. Hutson, P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
2. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
3. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
4. B.I. Rini, P. Escudier, A. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of a phase III AXIS trial J Clin Oncol 29 suppl 2011 abstract 4503 http://www.asco.org Accessed: April 25, 2013
5. B. Escudier, J. Bellmunt, S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
6. J.I. Izawa, C.P. Dinney The role of angiogenesis in prostate and other urologic cancers: a review CMAJ 164 2001 662 670
7. J.W. Slaton, Inoue, P. Perrotte Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma Am J Pathol 158 2001 735 743
8. J.C. Yang, L. Haworth, R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
9. Avastin [Genentech, Inc] 2013 FDA package insert South San Francisco, CA
10. E.A. Eisenhauer, P. Therasse, J. Bogaerts New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
11. R.M. Bukowski, F.F. Kabbinovar, R.A. Figlin Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 2007 4536 4541
12. E. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
13. R.J. Motzer, M. Mazumbar, J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
14. X. Na, G. Wu, C.K. Ryan Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas J Urol 170 2003 588 592
15. B.I. Rini, S. Halabi, J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143